In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Sano Corp.

Division of Perrigo Co. PLC

Latest From Sano Corp.

Cygnus' Comeback in Non-Invasive Testing

Cygnus is one of 1999's few great turnaround stories. A year ago, it was on the verge of collapse, but now it is about to get FDA approval of the first non-invasive glucose monitor for diabetes. Next, Cygnus needs to find a corporate partner without giving up too much, and to determine the true market potential of its device, the GlucoWatch Biographer, which got approved as an adjunct to, not a replacement for, traditional blood-glucose testing.
BioPharmaceutical Medical Device

Broad, Broader, Broadest: Drug Delivery Start-Ups

Drug delivery start-ups abound, despite the harsh environment for new biopharmaceutical companies. Drug delivery deals are increasing, as are relatively highly valued acquisitions, as larger drug delivery or service companies seek to broaden their tool kits. But for companies who haven't yet proven themselves, dealmaking is difficult in a variety of ways. Credibility is tough to achieve.
BioPharmaceutical Business Strategies

Yamanouchi's Foray Into Drug Delivery

Yamanouchi attempts to use its drug delivery business (Yamanouchi Shaklee Pharma) to help jumpstart its efforts to gain a foothold in the US and to eventually become a true global player. Yamanouchi's support of YSP may, however, be a two-edged sword: it provides YSP with the kind of financial support that most drug delivery companies can only dream of, but it may also scare off potential partners.
BioPharmaceutical North America

Why the Drug Delivery Industry Can Consolidate

Drug delivery companies have been consolidating with a fury over the last twelve months, unlike biotechs. The difference: delivery firms have plenty of drug service companies to sell to (other drug delivery firms, distributors, generic houses), while biotechs can only sell to Big Pharma--which doesn't want to buy them.
BioPharmaceutical Business Strategies
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Therapeutic Areas
  • Alias(es)
  • Ownership
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Perrigo Co. PLC
  • Senior Management
  • Gerard Coombs, CFO
    Marc Watson, Chmn.
    Reginald Hardy, Pres.
    Charles Betlach, SVP, R&D
  • Contact Info
  • Sano Corp.
    Phone: (954) 430-3340
    3250 Commerce Pkwy.
    Miramar, FL 33025